Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2012

View Archived Issues

Lorvotuzumab mertansine evaluated in patients with solid tumors

Merck KGaA discloses novel agents for cancer

GlaxoSmithKline patents new RIP-2 inhibitors

Daiichi Sankyo divulges new Mdm2/p53 inhibitors

Novel AMPK activators synthesized at GlaxoSmithKline

Japanese researchers disclose new glucokinase activators

Plavix gets Japanese approval for additional indication

Intramuscular injection formulation of Zyprexa approved in Japan

Biotie Therapies describes novel SSAO inhibitors

Suini approved in Japan for type 2 diabetes

Bayer HealthCare joins forces with Evotec on endometriosis

Shionogi and Kotobuki Pharmaceutical sign license agreement for cholesterol absorption inhibitor

Ramucirumab shows activity in non-small cell lung cancer

Progenics Pharmaceuticals begins phase II PSMA-ADC trial in prostate cancer

Dacogen gains approval in the E.U. for acute myeloid leukemia

Results of lenvatinib trials in different kinds of cancer presented

Humira obtains new approval in the U.S.

Novo Nordisk discontinues development of vatreptacog alfa

Subcutaneous Velcade approved in Europe for multiple myeloma

Novo Nordisk's insulin degludec obtains first approval

Antisense Therapeutics provides update on ATL-1102 collaboration

Medicure to develop transdermal formulation of Aggrastat

Apricus Biosciences plans Canadian submission for MycoVa

FDA approval sought for tivozanib

A.P. Pharma resubmits APF-530 NDA

European approval for Seebri Breezhaler